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ABSTRACT
Introduction Although paediatric patients have an
increased risk for adverse drug events, few detection
methodologies target this population. To utilise
computerised adverse event surveillance, specialised
trigger rules are required to accommodate the unique
needs of children. The aim was to develop new, tailored
rules sustainable for review and robust enough to
support aggregate event rate monitoring.
Methods The authors utilised a voluntary staff incident-
reporting system, lab values and physician insight to
design trigger rules. During Phase 1, problem areas were
identiﬁed by reviewing 5 years of paediatric voluntary
incident reports. Based on these ﬁndings, historical lab
electrolyte values were analysed to devise critical value
thresholds. This evidence informed Phase 2 rule
development. For 3 months, surveillance alerts were
evaluated for occurrence of adverse drug events.
Results In Phase 1, replacement preparations and total
parenteral nutrition comprised the majority (36.6%) of
adverse drug events in 353 paediatric patients. During
Phase 2, nine new trigger rules produced 225 alerts in
103 paediatric inpatients. Of these, 14 adverse drug
events were found by the paediatric hypoglycaemia rule,
but all other electrolyte trigger rules were ineffective.
Compared with the adult-focused hypoglycaemia rule,
the new, tailored version increased the paediatric event
detection rate from 0.43 to 1.51 events per 1000 patient
days.
Conclusions Relying solely on absolute lab values to
detect electrolyte-related adverse drug events did not
meet our goals. Use of compound rule logic improved
detection of hypoglycaemia. More success may be found
in designing real-time rules that leverage lab trends and
additional clinical information.
INTRODUCTION
Compared with adults, less information is available
on the epidemiology of paediatric adverse drug
events (ADEs), although they are more likely to
occur.
1 ADE rates ranging from 6.6 to 15.7 events
per 1000 patient days have been reported for
paediatric inpatients.
2e4 Guiding agencies have
suggested adoption of health information tech-
nology (HIT) tools to reduce medical errors, but the
lack of paediatric-speciﬁc information to develop
standards remains a barrier.
1
Duke University Hospital (DUH) employs two
ADE detection systems: a voluntary safety
reporting system (SRS) and computerised ADE
surveillance (ADE-S).
5e7 SRS is a web application
where staff report safety incidents, whereas
surveillance applies trigger logic to medical records
and notiﬁes of potential ADEs.
56In paediatrics,
ADE-S did not outperform SRS in ADE detection as
it does in adults.
568 e10 The ADE detection rate by
surveillance is over four times that of paediatrics,
despite the expected higher incidence of events.
56
Paediatric HIT products should rely on independent
data and not extrapolation from adults.
1 This
deﬁciency, as well as the low paediatric ADE
detection rate using adult-focused triggers, clearly
demonstrates a need for rules tailored to paediatric
care. Our goal was to devise paediatric-focused
trigger rules that are both sustainable at DUH and
productive enough to serve as a longitudinal safety
indicator. To meet these objectives, trigger rules
must have the following design criteria: (1) objec-
tive evidence of harm inferable from the medical
record, (2) reviewer time investment justiﬁed by
alert volume and true positive rate, and (3) poten-
tial to generate sufﬁcient ADE data for monthly
rate trending. We retooled surveillance using insight
from voluntary reporting, lab results and guidance
from practising paediatricians.
METHODS
Study design
We performed a retrospective, cross-sectional study
at DUH, a tertiary care teaching hospital having
seven paediatric inpatient units (three intensive-
care units (ICUs), two general care, two transi-
tional care). We deﬁned an ADE as an ‘injury
resulting from the use of a drug.’
11 Phase 1 entailed
a three-pronged approach for rule development:
review of historical ADEs, analysis of lab data and
paediatrician consultation. New surveillance rules
were implemented in Phase 2. This study was
approved by the Duke University Health System
Institutional Review Board.
Phase 1
Medication-related voluntary reports to SRS are
routinely investigated by clinical pharmacists and
scored for severity (table 1).
5 Many hospitals turn
to voluntary reporting to ﬁnd emerging risk
areas
12e14 despite reporter bias in the data.
15 16 We
reviewed inpatient paediatric (age <18) ADEs
reported to SRS between 12 January 2002 and 12
September 2007, and grouped them by primary
medication class. We examined classes with the
greatest event volume, not the highest ADE rate,
since voluntary reporting is not a quantitative
metric.
Given that electrolyte preparations and total
parenteral nutrition/lipids (TPN/lipids) were
primary causes of ADEs, we gathered paediatric lab
results for ionised calcium, chloride, magnesium,
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Original researchpotassium, sodium and triglycerides from 1 August 2005 to 31
August 2007 to pinpoint critical values for trigger logic. Total
bilirubin was examined as well, given concern regarding neonate
monitoring.
17 We plotted histograms showing the distribution
of lab value results (ﬁgure 1). As with development of any
alerting functionality, balance between event detection and alert
volume is necessary to ensure sustainability. For most labs, the
upper and lower 0.5% of distributions deﬁned critical values for
rule development. For ionised calcium, the upper 2.5% was
selected as the critical value given the shape of the distribution.
Although the upper 0.5 percentile for triglycerides was 1376 mg/
dl, this threshold would generate few triggers each month,
which deﬁes our design requirement for trigger volume. Conse-
quently, we sought guidance, and 500 mg/dl was suggested as
a threshold by the clinical administrator of SRS, who is also
a practising neonatologist at DUH.
An additional rule was developed given a known issue with
ADE-S detection of hypoglycaemia. The existing rule was based
on the adult protocol to administer dextrose 50% as an antidote
to low blood glucose (BG). However, most paediatric protocols
do not call for this drug. The paediatric hypoglycaemia-related
ADE rate at DUH is only 0.08 events per 1000 patient days
compared with 4.47 events per 1000 patient days in adults.
5 6
Therefore, we created a paediatric rule to alert for BG<50 mg/dl
concomitant with an insulin order. We did not include oral
hypoglycaemic agents in this logic, since nearly 90% of DUH
hypoglycaemic events are due to insulin.
Phase 2
The DUH ADE-S system has been described previously.
5 61 01 8
Each evening ADE-S reviews the electronic records of all DUH
inpatients to identify potential ADEs. Clinical pharmacists
perform a chart review to conﬁrm ADE occurrence (ie, docu-
mented patient harm). Events are scored by three pharmacist
reviewers (k$0.88) for severity (table 1)
5 and causality.
19
Paediatric-speciﬁc rules were evaluated between 27 November
2007 and 12 February 2008. Fifteen days were excluded due to
reviewer unavailability.
Data analysis
Phase 1 lab data histograms were created using JMP 7.0 (SAS
Institute, Cary, North Carolina). Phase 2 analysis included all
alerts for patients discharged from a paediatric location. Positive
predictive values (PPVs) were calculated as the percentage of
alerts deemed ADEs subsequent to evaluation. Rates were
calculated as ADEs per 1000 patient days. The Fisher exact test
was used to seek signiﬁcant differences in categorical data. CIs
were calculated using the binomial approximation. Where
appropriate, the ADE yields of the new and old trigger rules were
cross-compared.
RESULTS
Phase 1: Review of historical ADE data and critical lab values
SRS documents 385 medication-related ADEs occurring in 353
paediatric patients from 12 January 2002 to 12 September 2007
Figure 1 Histograms showing the
distribution of paediatric lab test results.
The distributions of paediatric lab test
values for (a) potassium, (b) ionised
calcium, (c) chloride and (d) magnesium
were examined over a 2-year time
period. Chloride, triglycerides and total
bilirubin were examined but are not
shown. In each graph, the vertical axis
comprises the counts of lab results. The
arrows represent the thresholds for the
upper or lower 0.5% of all test results
(upper 2.5% for calcium, B). These
values were considered extreme outliers
and guided trigger rule logic. Accepted
reference values for each test were
dependent on age, but the most
common ranges are shown.
Table 1 Duke University Hospital 7-point severity scoring system for
patient harm
Score Severity deﬁnitions
0 Caught before reached patient, but a system failure occurred
1 Reached patient, but there were no patient effects or consequences to
medication use system; single dose or infusion problem >4h
2 Reached patient, there were no detectable patient effects, but change(s)
occurred in medication schedule dosing, duration or monitoring; multiple doses
or infusion problem >4h
3 Transient adverse patient effects occurred that required some corrective
therapy, increased length of stay by 1 to 2 days, or resulted in laboratory
values, vital signs or medication effects outside desirable parameters. A
severity of 3 or greater is considered an adverse drug event if there is evidence
that a drug is at fault.
4 Signiﬁcant adverse patient effects occurred that required aggressive
intervention, such as code, intubation, transfer to intensive-care unit,
interventional drug therapy or increased length of stay >2 days
5 Permanent adverse patient effects occurred, such as paralysis, brain damage,
disability or loss of limb, organ or bodily function
6 Patient death
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Original research(table 2). Electrolyte preparations and TPN/lipids account for
24.4% (94/385) and 12.2% (47/385) of events, respectively.
Representative cases include an incident where dispensing of
dextrose-containing intravenous ﬂuids was delayed, resulting in
a BG of 27 mg/dl and administration of an interventional
glucose bolus to reverse hypoglycaemia. The American Diabetes
Association holds that hypoglycaemia, regardless of symptoms,
harms the patient.
20 Another patient developed premature atrial
contractions from hyperkalaemia due to failure to discontinue
potassium-containing intravenous ﬂuids. This event was scored
a severity of 3, since transient adverse effects occurred, and
corrective therapy was used to lower the potassium level.
From 1 August 2005 to 31 August 2007, over 450000 lab
results for paediatric inpatients were available for ionised
calcium, chloride, magnesium, potassium, sodium, total bili-
rubin and triglycerides. Figure 1 shows histograms for these
results as well as the outlier values selected.
Phase 2: Implementation of paediatric-speciﬁc ADE-S trigger
rules
Development of paediatric-speciﬁc trigger rules (table 3) was
guided by Phase 1 results. Only two of the original adult-
designed rules involve electrolytes: dextrose 50% with a BG
<50 mg/dl (A1) and an order for polystyrene, a reversal agent for
elevated potassium levels (A2). Between 27 November 2007 and
12 February 2008, DUH had 796 paediatric admissions and 9270
patient days across the general care (41% of patient days), ICU
(53% of patient days) and transitional care (6% of patient days)
environments. These visits produced 225 trigger alerts (rules
P1eP9) for 103 patients (table 3). Fourteen alerts from the
hypoglycaemia rule (P9) were deemed ADEs following chart
review (PPV¼6.2%). The electrolyte-based rules did not detect
ADEs, as no objective evidence of harm was documented.
Both the adult- (A1) and paediatric-focused (P9) rules for
hypoglycaemia were active to evaluate differential ADE capture.
A total of 30 triggers ﬁred on paediatric units from these two
rules (table 3). Some alerts were not deemed ADEs due to
erroneous BG readings or undocumented insulin administration
despite an active order. The PPVs for both P9 and A1 were
similar (60.8% and 57.1%), yet a greater number of ADEs were
detected with the paediatric rule (1.51 vs 0.43 events per 1000
patient days, p¼0.03). All ADEs captured by the adult rule were
detected using the paediatric-focused logic.
DISCUSSION
Our goal was to combine clinical evidence and provider insight
to develop a sustainable, paediatric-relevant surveillance model
that yields trendable data for ADE monitoring. A review of
voluntarily reported safety incidents revealed electrolyte and
TPN/lipid preparations underlie many ADEs. No rule targeting
lab abnormalities detected ADEs in this study, although we
improved hypoglycaemia ADE capture.
Our results are consistent with other paediatric trigger
development efforts. Sharek and colleagues developed a neonatal
intensive care unit (NICU)-focused manual tool for adverse
event discovery.
21 They included rule logic for rising creatinine
(PPV¼11%) and an ‘abnormal electrolytes’ rule with a PPV of
8%. Since this latter rule is not retained in the trigger tool online
(http://www.chca.com), we infer it was ineffective. A second
trigger tool for paediatrics was deployed across 12 children’s
hospitals,
4 and compound rule logic produced better PPVs.
Although a single-value hyperglycaemia trigger resulted in a PPV
of only 0.60%, combining absolute lab values with age logic to
detect hyperkalaemia or nephrotoxicity resulted in PPVs of
3.57% and 3.85%. A recent study modifying a surveillance
system for paediatrics had limited success with ADE detection
using hypokalaemia and hypomagnesaemia rules.
22 The authors
also report a PPV of 0.08 for hyperkalaemia combined with age
logic (potassium >6.0 mEq/l and age >1 year), whereas our PPV
for potassium >7.0 mEq/l was 0.
These studies indicate that the use of compound rule logic
improves paediatric ADE discovery. At DUH, the issue with
using absolute lab values for ADE-S may lie in how they are
drawn. For example, NICU heel sticks are used to obtain small
blood samples, yet they frequently haemolyse, resulting in
elevated potassium values. In the case of elevated lipid levels, the
nurse may have drawn the sample from the line infusing lipids.
Such details go undocumented, meaning relying on lab values
retrospectively to suggest that ADE occurrence is ineffective for
our goals. Options to improve rules using compound logic
include reasoning over lab value changes (eg, rising bilirubin),
since utilising more than two values may bypass unwanted
alerts from a single, aberrant result. Additionally, concomitant
active drug orders and lab results (eg, use of electrolyte prepa-
rations, potassium supplements, or potassium-sparing diuretics
and hyperkalaemia) may be of value. Institutions with text
scanning capabilities may be able to combine keywords from the
medical record relevant to a lab result (eg, altered mental status
and the presence of hyponatremia). Since ADE-S runs in a batch
process, we are evaluating logistics for real-time alerting of
concerning lab trends. Takata and colleagues reported two-thirds
of their ADEs were due to lapses in monitoring medications,
including assessment of lab results.
4 This series of strategies may
reduce false-positive alerts and improve ADE detection.
Although lowering lab value thresholds may capture more
ADEs, the expected increase in alert volume without improving
the PPV would be a barrier to sustainable reviewda central goal
of this study.
There are several limitations to this work. DUH has a large
paediatric ICU population (53% of study patient days), which
accounts for 61% of trigger alerts. This may limit the general-
isability of our ﬁndings to hospitals with a similar composition,
yet these are likely the same facilities that would have IT
resources to implement a computerised surveillance programme.
A second limitation is that rules were evaluated over
2.5 months, which may have under-represented detection of rare
ADEs. The authors felt that 2.5 months was adequate to eval-
uate alert utility given the goals of (1) sustainability and (2) data
capture for aggregate ADE rate monitoring. Though not useful
for our purposes, other organisations may have more success
with these rules if able to sustain a longer study period.
However, a recent 6-month study with over 40000 patient days
Table 2 Inpatient paediatric adverse drug events found by voluntary
reporting (n¼385)
Event location No (%)
Critical care unit 257 (66.8)
General care unit 128 (33.2)
Medication category No (%)
Electrolyte preparations 94 (24.4)
Total parenteral nutrition/lipids 47 (12.2)
Anti-infectives: antibiotics 45 (11.7)
Cardiac drugs 37 (9.6)
Narcotics and benzodiazepines 36 (9.4)
Other* 126 (32.7)
*Other includes 20 categories, such as anticoagulants, vaccines, anticonvulsants, and
antineoplastics.
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Original researchsimilarly reported low PPVs for electrolyte-based rules (except
hypokalaemia and hypomagnesaemia).
22 They also noted the
need to modify or eliminate low-performing rules to balance
reviewer effort and event discovery despite the possibility of rare
ADE detection.
22 A ﬁnal limitation to any surveillance approach
is its reliance on objective data in the medical record to conﬁrm
ADE occurrence. Near misses cannot be captured if errors did
not reach the patient.
CONCLUSION
Although computerised surveillance effectively detects ADEs,
developing paediatric rules based solely on critical lab values did
not meet our goals. However, enhancement of a hypoglycaemia
trigger rule signiﬁcantly increased our detection rate. Investiga-
tors should be encouraged not only to report their successes in
this area but also to describe ineffective approaches. The
sustainability of trigger evaluation should be a consideration for
any rule design. Development of compound rule logic may be
a worthwhile approach.
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